15 June 2015
Afrezza inhaled insulin has gone on sale in America.
Afrezza, developed by MannKind and licensed to pharmaceutical company Sanofi, is available in the US market for people with Type 1 or Type 2 diabetes on prescription as a bolus (mealtime) insulin.
The drug is not yet approved for children, people with chronic lung conditions, smokers or people outside the US. It is also not recommended for the treatment of DKA.
Afrezza is supplied as a dry formulation of human insulin delivered from a small and portable inhaler. Afrezza is rapidly absorbed and has a short duration of action. It is administered at the beginning of a meal.